REmote MOnitoring Transmission Evaluation of IPGs

Overview

The purpose of this study is to evaluate the potential clinical and economic benefits of using CareLink remote management for pacemaker follow-up. Study Objectives include: 1. To determine clinician perceived quality of care for CareLink remote follow-up. 2. To determine patient satisfaction with CareLink follow-up. 3. To estimate the time required to perform patient follow-up via CareLink remote transmissions. 4. To determine the percentage of regular CareLink follow-ups that do not require further in-clinic review of the patient. 5. To estimate potential patient cost avoidance for one year of follow up incorporating CareLink. 6. To evaluate compliance to scheduled CareLink transmissions with the remote management system This is a non-randomized, multi-center, prospective study in which 120 patients who have a pacemaker are enrolled into the study and receive a CareLink monitor. Patients will replace their regularly scheduled pacemaker clinic follow-up visits with a CareLink remote transmission for 12months. Patients will require a test transmission within 1 month after they receive their CareLink monitor. Afterwards, patients are followed via CareLink transmissions as per their usual clinic schedule for 12 months.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 2009

Interventions

  • Other: CareLink Remote Monitoring
    • Substitution of CareLink Remote Monitoring of Pacemakers for in-clinic pacemaker follow-up visits

Arms, Groups and Cohorts

  • Experimental: 1
    • Pacemaker Patients

Participating in This Clinical Trial

Inclusion Criteria

  • Patients who have received a market released Medtronic pacemaker with automatic threshold management features for all active leads. – Patients who have been implanted with their current pacemaker for at least 3 months. – Patients who are willing, or who have caregivers willing, to use the Medtronic CareLink Monitor. – Patients who are willing and able to sign an IRB/MEC approved patient informed consent. Exclusion Criteria:

  • Patients participating in another study that would affect the objectives of this study – Patients who have already previously used a Medtronic CareLink Monitor.

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Medtronic Cardiac Rhythm and Heart Failure
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.